Company profile
SCILEX HOLDING CO
NASDAQ:SCLXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ELYXYB | approved | — | 6 | approved |
| GLOPERBA | approved | — | 4 | approved |
| ZTLIDO | approved | — | 1 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (0)
No records yet.
FDA applications (3)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 212157 | 2020-05-05 | NDA | SCILEX PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 210942 | 2019-01-30 | NDA | SCILEX PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 207962 | 2018-02-28 | NDA | SCILEX PHARMACEUTICALS INC | |||||
Loading… | ||||||||